Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1)

NCT04301284 is registered in ClinicalTrials.gov with Cadent Therapeutics as lead sponsor.

NCT NCT04301284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04301284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1)
Lead sponsor
Cadent Therapeutics
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2021
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

arca1 - autosomal recessive cerebellar ataxia type 1, spinocerebellar ataxia type 1, spinocerebellar ataxia type 10, spinocerebellar ataxia type 17, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 8, spinocerebellar ataxias